Brookline Capital Markets Estimates UNCY Q4 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Stock analysts at Brookline Capital Markets issued their Q4 2026 EPS estimates for Unicycive Therapeutics in a note issued to investors on Monday, November 16th. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings per share of ($0.28) for the quarter. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.14) per share. Brookline Capital Markets also issued estimates for Unicycive Therapeutics’ FY2027 earnings at $3.93 EPS, FY2028 earnings at $3.46 EPS, FY2029 earnings at $4.35 EPS and FY2030 earnings at $3.33 EPS.

Other equities research analysts have also issued research reports about the stock. HC Wainwright dropped their target price on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. Zacks Research raised shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Wall Street Zen lowered shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 14th. B. Riley Financial restated a “buy” rating and set a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, September 4th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $18.25.

Check Out Our Latest Report on Unicycive Therapeutics

Unicycive Therapeutics Stock Performance

Shares of UNCY opened at $3.57 on Thursday. The stock has a 50 day moving average price of $4.11 and a 200 day moving average price of $5.89. Unicycive Therapeutics has a one year low of $3.33 and a one year high of $8.74. The stock has a market capitalization of $104.19 million, a price-to-earnings ratio of -2.14 and a beta of 1.91.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.10.

Institutional Trading of Unicycive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC raised its holdings in shares of Unicycive Therapeutics by 412.4% during the 3rd quarter. Virtu Financial LLC now owns 59,484 shares of the company’s stock worth $279,000 after acquiring an additional 47,874 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Unicycive Therapeutics by 80.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 262,767 shares of the company’s stock valued at $1,234,000 after acquiring an additional 117,463 shares during the last quarter. Chicago Partners Investment Group LLC grew its holdings in shares of Unicycive Therapeutics by 26.0% in the third quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company’s stock valued at $105,000 after purchasing an additional 5,556 shares during the period. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Unicycive Therapeutics in the third quarter valued at about $36,000. Finally, Seven Fleet Capital Management LP grew its holdings in shares of Unicycive Therapeutics by 85.6% in the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after purchasing an additional 47,700 shares during the period. 40.42% of the stock is owned by institutional investors and hedge funds.

Latest Unicycive Therapeutics News

These are some of the UNCY news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its estimates for several periods, including FY2026 EPS to ($1.13) from ($1.38) and FY2027 to ($0.71) from ($0.86), while maintaining a Buy rating and $13 price target. The improved estimates could support sentiment. MarketBeat
  • Neutral Sentiment: Brookline Capital Markets issued markedly more optimistic long-range forecasts, projecting positive EPS from FY2027 onward. These are analyst projections and differ substantially from HC Wainwright’s outlook, so they add uncertainty rather than a clear consensus signal. MarketBeat
  • Negative Sentiment: Noble Financial lowered its FY2026 EPS estimate to ($0.80) from ($0.62), including a deeper projected Q4 loss. HC Wainwright also cut its FY2028–FY2030 EPS forecasts substantially, although it retained its Buy rating and $13 target; these longer-term reductions may weigh on investor expectations. MarketBeat

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Featured Articles

Earnings History and Estimates for Unicycive Therapeutics (NASDAQ:UNCY)

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.